Announced Tue, 12 May · 17:20 IST

Intimation regarding ESOP Compensation Committee Meeting

Board & Shareholder Meetings View source PDF

GLAND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.1%1-day move

₹1875.00

prior close

₹1870.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-1.4-1.5-1.5-1.5+1.1-1.0+14.8+19.3+18.2+24.0+18.7+17.8+31.2—

Up moveDown movePending

AI summary

Gland Pharma has informed exchanges that its ESOP Compensation Committee will meet on May 15, 2026 to consider and approve the grant of stock options under the company's Employee Stock Option Scheme 2025 (ESOP 2025). This is a routine pre-meeting intimation as required under listing regulations. The filing is dated May 12, 2026, signed by Company Secretary Sampath Kumar Pallerlamudi. No specific details about the number of options or eligible employees have been disclosed at this stage.

Likely market impact

This is a routine procedural filing with minimal direct impact on stock price. ESOP grants can create minor equity dilution but are standard practice to align employee and shareholder interests. Actual impact will depend on the size of the grant once approved.